ZhengGuo Cao

Dr. ZhengGuo Cao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2024 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YYYongkang Ye
Yongkang Ye
FYFukan Yang
Fukan Yang
ZGZhanhao Gu
Zhanhao Gu
WLWenxuan Li
Wenxuan Li
YYYinjiao Yuan
Yinjiao Yuan
ZCZhengGuo Cao
ZhengGuo Cao
Background: The initiation of fibroblast growth factor 1 (FGF1) expression coincident with the decrease of FGF2 expression is a well-documented event in prostate cancer (PCa) progression. Lactate dehydrogenase A (LDHA) and LDHB are essential metabolic products that promote tumor growth. However, the relationship between FGF1/FGF2 and LDHA/B-mediated glycolysis in PCa progression is not reported. Thus, we aimed to explore whether FGF1/2 could regulate LDHA and LDHB to promote glycolysis and explored the involved signaling pathway in PCa progression. Methods: In vitro studies used RT‒qPCR, Western blot, CCK-8 assays, and flow cytometry to analyze gene and protein expression, cell viability, apoptosis, and cell cycle in PCa cell lines. Glycolysis was assessed by measuring glucose consumption, lactate production, and extracellular acidification rate (ECAR). For in vivo studies, a xenograft mouse model of PCa was established and treated with an FGF pathway inhibitor, and tumor growth was monitored. Results: FGF1, FGF2, and LDHA were expressed at high levels in PCa cells, while LDHB expression was low. FGF1/2 positively modulated LDHA and negatively modulated LDHB in PCa cells. The depletion of FGF1, FGF2, or LDHA reduced cell proliferation, induced cell cycle arrest, and inhibited glycolysis. LDHB overexpression showed similar inhibitory effect on PCa cells. Mechanistically, we found that FGF1/2 positively regulated STAT1 and STAT1 transcriptionally activated LDHA expression while suppressed LDHB expression. Furthermore, the treatment of an FGF pathway inhibitor suppressed PCa tumor growth in mice. Conclusion: The FGF pathway facilitates glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in PCa.

7 April 2022 in Research Square
Verified
Preprint
Open access
PDF file
CTChao Tian
Chao Tian
GCGuiliu Chen
Guiliu Chen
ZCZhengGuo Cao
ZhengGuo Cao
Background: Patients with bladder cancer (BLCA), especially those with advanced stage cancer, have a short life span; thus, new drugs need to be developed urgently to improve the situation. Long noncoding RNAs (lncRNAs) are considered regulatory targets for cancer, including BLCA. Therefore, we constructed a promising signature of lncRNAs related to necroptosis and further predicted the immune response and sensitivity of drugs. Methods: We downloaded the transcriptome and clinical data for BLCA from the Cancer Genome Atlas(TCGA). Necroptosis related to lncRNAs (nrlncRNAs) was subsequently identified by univariate Cox regression. We then constructed the signature by performing the least absolute shrinkage and selection operator(LASSO) and evaluated it by Kaplan–Meier analysis, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), nomogram, calibration curves, gene set enrichment analyses(GSEA), immune checkpoint, tumor microenvironment(TME), N6-methyladenosine (m6A) modification genes, and the half-maximal inhibitory concentration (IC50) analysis in the risk groups. Results: An 11-nrlncRNAs (AC008750.1, AL133297.1, AC005479.1, AP003559.1, UBE2Q1-AS1, MIR100HG, LINC02709, AC005387.1, LINC00649, AC021321.1, ETV7-AS1) prognostic signature was constructed. Immune checkpoint analysis revealed that the expression of most of the immune genes in the high-risk group was higher than those in the low-risk group. The signature predicted different IC50 values to have statistical significance in high-and low-risk groups for multiple drugs. Conclusion: Our constructed signature may contribute to the prognosis of patients with BLCA as well as serve as clinical predictors of chemotherapy and immunotherapy.

7 April 2022 in Research Square
Verified
Preprint
Open access
PDF file
CTChao Tian
Chao Tian
GCGuiliu Chen
Guiliu Chen
ZCZhengGuo Cao
ZhengGuo Cao
Background: Patients with bladder cancer (BLCA), especially those with advanced stage cancer, have a short life span; thus, new drugs need to be developed urgently to improve the situation. Long noncoding RNAs (lncRNAs) are considered regulatory targets for cancer, including BLCA. Therefore, we constructed a promising signature of lncRNAs related to necroptosis and further predicted the immune response and sensitivity of drugs. Methods: We downloaded the transcriptome and clinical data for BLCA from the Cancer Genome Atlas(TCGA). Necroptosis related to lncRNAs (nrlncRNAs) was subsequently identified by univariate Cox regression. We then constructed the signature by performing the least absolute shrinkage and selection operator(LASSO) and evaluated it by Kaplan–Meier analysis, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), nomogram, calibration curves, gene set enrichment analyses(GSEA), immune checkpoint, tumor microenvironment(TME), N6-methyladenosine (m6A) modification genes, and the half-maximal inhibitory concentration (IC50) analysis in the risk groups. Results: An 11-nrlncRNAs (AC008750.1, AL133297.1, AC005479.1, AP003559.1, UBE2Q1-AS1, MIR100HG, LINC02709, AC005387.1, LINC00649, AC021321.1, ETV7-AS1) prognostic signature was constructed. Immune checkpoint analysis revealed that the expression of most of the immune genes in the high-risk group was higher than those in the low-risk group. The signature predicted different IC50 values to have statistical significance in high-and low-risk groups for multiple drugs. Conclusion: Our constructed signature may contribute to the prognosis of patients with BLCA as well as serve as clinical predictors of chemotherapy and immunotherapy.